- Udyam number
- UDYAM-TS-02-0041664

About Balaxi Pharmaceuticals Limited
Data last updated:
Balaxi Pharmaceuticals Limited is a public limited company based in Hyderabad, Telangana, India, a subsidiary of Balaxi Overseas Private Limited. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 28 September 1942 and has been in existence for over 84 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN L25191TG1942PLC121598. Its GSTIN is 36AABCA8305N1ZJ (Telangana). The company holds 2 GST registrations, all of them active. It is a listed company as per MCA records. Its shares are listed on NSE: BALAXI.
The company has an authorised share capital of ₹40 Cr and a paid-up capital of ₹11.04 Cr. It was formerly known as Balaxi Ventures Limited and Anandam Rubber Company Limited. It is led by directors including Ashish Maheshwari (Managing Director) and Mangina Srinivas Rao.
Its last annual general meeting (AGM) was held on 25 August 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Hyderabad, Telangana.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹270.17 Cr, a decline of 7.7% compared to the previous year. For the same year it recorded a net profit of ₹1.42 Cr (net margin 0.5%) and EBITDA of ₹8.52 Cr (EBITDA margin 3.2%). The net worth stands at ₹249.07 Cr (up 7.5% YoY). Total assets are valued at ₹306.97 Cr (up 7.6% YoY).
The company has about 80 employees on its provident fund (EPFO) records.
The company is associated with 3 brands: Balaxi Pharmaceuticals, Anandam Rubber Company and Balaxi. As per MCA filings, the company has open charges of ₹36.44 Cr and satisfied charges of ₹34.29 Cr on record. Court records list 1 case involving the company, including 1 filed by the company; 1 case is pending. The company has 13 deals on record (12 market trades, 1 funding round), with disclosed funding of ₹49.61 Cr; the latest was in March 2026. The company has 5 MSME Form 1 returns on record between 2023 and 2024, listing 368 overdue payments to 13 micro and small suppliers.
Balaxi Pharmaceuticals Limited is registered as an MSME under the Udyam registration framework (Reg. No. UDYAM-TS-02-0041664). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website balaxiventures.in.
Company details
Name history
Balaxi Pharmaceuticals has undergone 3 name changes throughout its history. The company was previously known as Balaxi Ventures Limited, Anandam Rubber Company Limited, and The Anandam Rubber Company Limited. The current legal name is Balaxi Pharmaceuticals Limited.
| Company Name | Status |
|---|---|
| Balaxi Pharmaceuticals Limited | Current |
| Balaxi Ventures Limited | Previous |
| Anandam Rubber Company Limited | Previous |
| The Anandam Rubber Company Limited | Previous |
CIN history
Balaxi Pharmaceuticals has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L25191TG1942PLC121598, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L25191TG1942PLC121598 | Current |
| U25191KL1942PLC000045 | Previous |
| L25191KL1942PLC000045 | Previous |
Recognitions & Rankings of Balaxi Pharmaceuticals
Contact details
Balaxi Pharmaceuticals Limited's registered office is in Hyderabad, Telangana. Its website is balaxiventures.in. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressPlot No.409 H.No. 8 – 2 – 293 Maps Towers 3rd Floor Phase – III Road No.81 Jubilee, Hills, Hyderabad, Telangana, India – 500096
- IndustryPharma, Pharmaceutical Retailers & Distributors
To see the full contact details of Balaxi Pharmaceuticals Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Balaxi Pharmaceuticals operates multiple associated brands including Balaxi Pharmaceuticals, Anandam Rubber Company, and Balaxi. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Agricultural operations, grain marketing, and equipment services by Balaxi. | balaxiventures.in | |
| Fabricated metal products are manufactured by Anandam Rubber Company. | anandamrubberco.com | |
| Drug distribution and storage services are provided by Balaxi. | balaxipharma.in |
Business activity
The main business activity of Balaxi Pharmaceuticals is wholesale and retail trade; repair of motor vehicles and motorcycles. In detail, this covers wholesale trade, except of motor vehicles and motorcycles.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Wholesale and retail trade; repair of motor vehicles and motorcycles | 46 | Wholesale trade, except of motor vehicles and motorcycles |
To see the full business activity and turnover split of Balaxi Pharmaceuticals Limited, buy the company report.
Financials of Balaxi Pharmaceuticals Limited
FY 2025-26 filings availableBalaxi Pharmaceuticals Limited reported revenue of ₹270.17 Cr (down 7.7% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 270 | 293 | 241 | 336 | 279 | 231 | 45.63 |
| Revenue growth | -7.7% | +21.3% | -28.3% | +20.4% | +20.8% | +407.0% | - |
| EBITDA | 8.52 | 32.22 | 6.23 | 57.41 | 50.81 | 42.67 | 8.25 |
| EBITDA margin | +3.2% | +11.0% | +2.6% | +17.1% | +18.2% | +18.5% | +18.1% |
| Profit before tax | 5.29 | 28.68 | 1.99 | 56.92 | 54.51 | 44.32 | 8.78 |
| Net profit | 1.42 | 25.16 | (49.85) | 45.96 | 47.65 | 38.13 | 6.09 |
| Net profit margin | +0.5% | +8.6% | -20.7% | +13.7% | +17.1% | +16.5% | +13.4% |
| EPS (₹) | 0.26 | 4.54 | (0.44) | 45.14 | 47.66 | 38.14 | 6.10 |
| Balance sheet | |||||||
| Total assets | 307 | 285 | 221 | 196 | 117 | 68.64 | 27.75 |
| Net worth | 249 | 232 | 201 | 183 | 113 | 64.98 | 27.75 |
| Total debt | 57.65 | 53.43 | 19.40 | 13.30 | 3.64 | 3.66 | 0.00 |
| Cash & bank | 14.56 | 39.40 | 62.29 | 28.22 | 7.19 | 1.67 | 4.00 |
| Net working capital | 223 | 219 | 174 | 151 | 81.37 | 62.74 | 26.62 |
| Cash flow | |||||||
| Cash from operations | (4.50) | (35.00) | 4.87 | 6.08 | 34.14 | 0.00 | (14.04) |
| Cash from investing | (20.78) | (21.76) | (1.05) | (10.57) | (28.45) | (5.97) | (0.18) |
| Cash from financing | 0.44 | 33.88 | 30.25 | 25.51 | (0.16) | 3.65 | 18.10 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 81.37 | 80.68 | 70.71 | 72.54 | 56.18 | 70.74 | 76.27 | 73.29 |
| Revenue growth (YoY) | +44.8% | +14.1% | -7.3% | -1.0% | -27.4% | +7.8% | - | - |
| Other income | (0.83) | (0.99) | 2.92 | 0.10 | 1.59 | (1.78) | (1.69) | 3.94 |
| EBITDA | 5.12 | 4.66 | 0.12 | 3.09 | 1.17 | 4.15 | 12.56 | 3.99 |
| EBITDA margin | +6.3% | +5.8% | +0.2% | +4.3% | +2.1% | +5.9% | +16.5% | +5.4% |
| Depreciation | 1.42 | 0.85 | 0.65 | 0.56 | 0.48 | 0.46 | 0.46 | 0.48 |
| Interest | 0.86 | 0.73 | 0.99 | 1.02 | 0.89 | 1.01 | 0.74 | 1.38 |
| Profit before tax | 2.01 | 2.09 | 1.40 | 1.61 | 1.39 | 0.90 | 9.67 | 6.07 |
| Tax | 0.87 | 0.80 | 0.79 | 1.30 | 1.16 | 0.61 | 1.02 | 0.71 |
| Net profit | 1.14 | 1.29 | 0.61 | 0.31 | 0.23 | 0.29 | 8.65 | 5.36 |
| EPS (₹) | 0.21 | 0.24 | 0.11 | 0.06 | 0.04 | 0.05 | 1.56 | 0.97 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 80.85 | 60.99 | 70.20 | 108 | 101 | 86.87 | 45.63 |
| Revenue growth | +32.6% | -13.1% | -35.1% | +6.8% | +16.6% | +90.4% | - |
| EBITDA | 0.76 | 2.61 | 5.35 | 16.87 | 17.30 | 19.02 | 8.65 |
| EBITDA margin | +0.9% | +4.3% | +7.6% | +15.6% | +17.1% | +21.9% | +19.0% |
| Profit before tax | 7.03 | 5.28 | 5.58 | 22.44 | 19.70 | 20.59 | 9.18 |
| Net profit | 5.15 | 3.60 | 3.69 | 16.21 | 14.67 | 15.13 | 6.49 |
| Net profit margin | +6.4% | +5.9% | +5.3% | +15.0% | +14.5% | +17.4% | +14.2% |
| EPS (₹) | 0.93 | 0.65 | 0.67 | 15.93 | 14.67 | 15.13 | 6.50 |
| Balance sheet | |||||||
| Total assets | 169 | 160 | 137 | 105 | 59.84 | 46.75 | 28.11 |
| Net worth | 133 | 128 | 122 | 92.11 | 57.91 | 43.25 | 28.11 |
| Total debt | 35.29 | 32.18 | 15.70 | 12.44 | 1.93 | 3.51 | 0.00 |
| Cash & bank | 5.33 | 28.69 | 44.06 | 17.88 | 0.84 | 0.48 | 3.57 |
| Net working capital | 48.31 | 106 | 107 | 74.94 | 32.04 | 26.52 | 26.91 |
| Cash flow | |||||||
| Cash from operations | 43.87 | (7.60) | (1.83) | (7.07) | 8.89 | 13.46 | (14.37) |
| Cash from investing | (67.77) | (24.98) | 0.46 | (2.29) | (6.87) | (20.03) | (0.28) |
| Cash from financing | 0.54 | 17.21 | 27.55 | 26.39 | (1.64) | 3.49 | 18.10 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26.29 | 15.58 | 20.24 | 24.59 | 19.31 | 16.71 | 9.65 | 11.16 |
| Revenue growth (YoY) | +36.2% | -6.8% | +109.7% | +120.3% | -8.7% | -12.2% | - | - |
| Other income | 1.08 | 0.92 | 3.37 | 1.62 | 4.21 | 0.46 | 0.32 | 2.92 |
| Total expenses | 25.96 | 16.58 | 22.17 | 23.21 | 18.54 | 16.17 | 10.30 | 11.06 |
| EBITDA | 0.33 | (1.00) | (1.93) | 1.38 | 0.77 | 0.54 | (0.65) | 0.10 |
| EBITDA margin | +1.3% | -6.4% | -9.5% | +5.6% | +4.0% | +3.2% | -6.7% | +0.9% |
| Depreciation | 0.59 | 0.59 | 0.31 | 0.15 | 0.12 | 0.11 | 0.11 | 0.11 |
| Interest | 0.57 | 0.45 | 0.71 | 0.73 | 0.62 | 0.63 | 0.69 | 0.57 |
| Profit before tax | 0.25 | (1.12) | 0.42 | 2.12 | 4.24 | 0.26 | (1.13) | 2.34 |
| Tax | 0.14 | 0.14 | 0.26 | 0.59 | 0.97 | 0.06 | 0.04 | 0.59 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 81.37 | 80.68 | 70.71 | 72.54 | 56.18 | 70.74 | 76.27 | 73.29 |
| Revenue growth (YoY) | +44.8% | +14.1% | -7.3% | -1.0% | -27.4% | +7.8% | - | - |
| Other income | (0.83) | (0.99) | 2.92 | 0.10 | 1.59 | (1.78) | (1.69) | 3.94 |
| EBITDA | 5.12 | 4.66 | 0.12 | 3.09 | 1.17 | 4.15 | 12.56 | 3.99 |
| EBITDA margin | +6.3% | +5.8% | +0.2% | +4.3% | +2.1% | +5.9% | +16.5% | +5.4% |
| Depreciation | 1.42 | 0.85 | 0.65 | 0.56 | 0.48 | 0.46 | 0.46 | 0.48 |
| Interest | 0.86 | 0.73 | 0.99 | 1.02 | 0.89 | 1.01 | 0.74 | 1.38 |
| Profit before tax | 2.01 | 2.09 | 1.40 | 1.61 | 1.39 | 0.90 | 9.67 | 6.07 |
| Tax | 0.87 | 0.80 | 0.79 | 1.30 | 1.16 | 0.61 | 1.02 | 0.71 |
| Net profit | 1.14 | 1.29 | 0.61 | 0.31 | 0.23 | 0.29 | 8.65 | 5.36 |
| EPS (₹) | 0.21 | 0.24 | 0.11 | 0.06 | 0.04 | 0.05 | 1.56 | 0.97 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 270 | 293 | 241 | 336 | 279 | 231 | 45.63 |
| Revenue growth | -7.7% | +21.3% | -28.3% | +20.4% | +20.8% | +407.0% | - |
| Other income | 2.82 | 2.36 | 0.63 | 2.64 | 4.97 | 2.23 | 0.59 |
| Total expenses | 262 | 260 | 235 | 279 | 229 | 189 | 37.38 |
| Employee cost | 0.00 | 34.74 | 28.04 | 28.95 | 12.47 | 8.47 | 2.10 |
| EBITDA | 8.52 | 32.22 | 6.23 | 57.41 | 50.81 | 42.67 | 8.25 |
| EBITDA margin | +3.2% | +11.0% | +2.6% | +17.1% | +18.2% | +18.5% | +18.1% |
| Depreciation | 2.15 | 1.89 | 2.10 | 1.75 | 0.51 | 0.30 | 0.01 |
| Interest | 3.90 | 4.01 | 2.77 | 1.38 | 0.76 | 0.28 | 0.05 |
| Profit before tax | 5.29 | 28.68 | 1.99 | 56.92 | 54.51 | 44.32 | 8.78 |
| Tax | 3.87 | 3.60 | 4.40 | 10.96 | 6.86 | 6.19 | 2.69 |
| Net profit | 1.42 | 25.16 | (49.85) | 45.96 | 47.65 | 38.13 | 6.09 |
| Net profit margin | +0.5% | +8.6% | -20.7% | +13.7% | +17.1% | +16.5% | +13.4% |
| EPS (₹) | 0.26 | 4.54 | (0.44) | 45.14 | 47.66 | 38.14 | 6.10 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 11.04 | 11.04 | 10.90 | 10.18 | 10.00 | 10.00 | 10.00 |
| Reserves & surplus | 238 | 221 | 187 | 162 | 103 | 54.98 | 17.75 |
| Shareholders' funds (net worth) | 249 | 232 | 201 | 183 | 113 | 64.98 | 27.75 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 1.30 | 0.00 | 0.00 | 0.07 | 0.13 | 0.15 | 0.00 |
| Unsecured loans | 56.35 | 53.43 | 19.40 | 13.23 | 3.51 | 3.51 | 0.00 |
| Total debt | 57.65 | 53.43 | 19.40 | 13.30 | 3.64 | 3.66 | 0.00 |
| Total liabilities | 307 | 285 | 221 | 196 | 117 | 68.64 | 27.75 |
| Assets | |||||||
| Gross block | 85.81 | 42.88 | 42.98 | 43.00 | 29.23 | 2.74 | 0.19 |
| Net block | 81.68 | 40.99 | 40.88 | 41.40 | 28.76 | 2.44 | 0.19 |
| Capital work in progress | 0.00 | 22.07 | 2.31 | 2.83 | 0.57 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.42 | 0.00 |
| Inventories | 83.48 | 78.48 | 82.17 | 105 | 98.70 | 13.62 | 0.83 |
| Sundry debtors | 136 | 111 | 55.71 | 52.28 | 27.56 | 76.76 | 29.71 |
| Cash & bank balances | 14.56 | 39.40 | 62.29 | 28.22 | 7.19 | 1.67 | 4.00 |
| Loans & advances | 17.29 | 14.09 | 10.01 | 7.99 | 7.55 | 1.72 | 0.31 |
| Total current assets | 251 | 243 | 210 | 194 | 141 | 93.77 | 34.85 |
| Total current liabilities | 28.73 | 24.15 | 36.53 | 42.39 | 59.63 | 31.03 | 8.23 |
| Net working capital | 223 | 219 | 174 | 151 | 81.37 | 62.74 | 26.62 |
| Total assets | 307 | 285 | 221 | 196 | 117 | 68.64 | 27.75 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 39.40 | 62.29 | 28.21 | 7.19 | 1.66 | 3.98 | 0.10 |
| Net cash from operating activities | (4.50) | (35.00) | 4.87 | 6.08 | 34.14 | 0.00 | (14.04) |
| Net cash from investing activities | (20.78) | (21.76) | (1.05) | (10.57) | (28.45) | (5.97) | (0.18) |
| Net cash from financing activities | 0.44 | 33.88 | 30.25 | 25.51 | (0.16) | 3.65 | 18.10 |
| Net change in cash | (24.84) | (22.89) | 34.07 | 21.02 | 5.53 | (2.32) | 3.88 |
| Closing cash | 14.56 | 39.40 | 62.29 | 28.22 | 7.19 | 1.67 | 4.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -7.7% | +21.3% | -28.3% | +20.4% | +20.8% | +407.0% | - |
| EBITDA growth | -73.6% | +417.2% | -89.2% | +13.0% | +19.1% | +417.2% | - |
| PBT growth | -81.6% | +1340.7% | -96.5% | +4.4% | +23.0% | +404.8% | +258.4% |
| Net income growth | -94.4% | +150.5% | -208.5% | -3.6% | +25.0% | +526.1% | - |
| Revenue CAGR (3Y) | -7.1% | +1.6% | +1.4% | +94.6% | +173.9% | - | - |
| EBITDA CAGR (3Y) | -45.0% | -9.0% | -47.3% | +90.9% | +219.4% | - | - |
| Profitability & leverage | |||||||
| Net income margin | +0.5% | +8.6% | -1.0% | +13.7% | +17.1% | +16.5% | +13.4% |
| Return on capital employed | +3.5% | +12.9% | +20.7% | +37.3% | +59.6% | +92.6% | +56.5% |
| Return on net worth | +0.6% | +11.6% | -25.9% | +31.1% | +53.5% | +82.3% | +39.0% |
| Debt / equity | 0.23 | 0.17 | 0.09 | 0.06 | 0.04 | 0.04 | 0.00 |
| Long-term debt / equity | 0.10 | 0.06 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Interest cover | 66.85 | 11.02 | 67.07 | 2.48 | 1.51 | 0.66 | 0.61 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 4.20 | 6.81 | 5.61 | 9.32 | 17.48 | 157.90 | 456.30 |
| Inventory turnover | 3.34 | 3.64 | 2.58 | 3.30 | 4.97 | 32.02 | 109.95 |
| Debtors turnover | 2.19 | 3.51 | 4.47 | 8.43 | 5.36 | 4.35 | 2.59 |
| EPS (₹) | 0.26 | 4.54 | (0.44) | 45.14 | 47.66 | 38.14 | 6.10 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.50 | 0.00 | 0.00 |
| Book value per share (₹) | 45.12 | 41.98 | 36.26 | 169.51 | 113.16 | 64.98 | 27.75 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26.29 | 15.58 | 20.24 | 24.59 | 19.31 | 16.71 | 9.65 | 11.16 |
| Revenue growth (YoY) | +36.2% | -6.8% | +109.7% | +120.3% | -8.7% | -12.2% | - | - |
| Other income | 1.08 | 0.92 | 3.37 | 1.62 | 4.21 | 0.46 | 0.32 | 2.92 |
| Total expenses | 25.96 | 16.58 | 22.17 | 23.21 | 18.54 | 16.17 | 10.30 | 11.06 |
| EBITDA | 0.33 | (1.00) | (1.93) | 1.38 | 0.77 | 0.54 | (0.65) | 0.10 |
| EBITDA margin | +1.3% | -6.4% | -9.5% | +5.6% | +4.0% | +3.2% | -6.7% | +0.9% |
| Depreciation | 0.59 | 0.59 | 0.31 | 0.15 | 0.12 | 0.11 | 0.11 | 0.11 |
| Interest | 0.57 | 0.45 | 0.71 | 0.73 | 0.62 | 0.63 | 0.69 | 0.57 |
| Profit before tax | 0.25 | (1.12) | 0.42 | 2.12 | 4.24 | 0.26 | (1.13) | 2.34 |
| Tax | 0.14 | 0.14 | 0.26 | 0.59 | 0.97 | 0.06 | 0.04 | 0.59 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 80.85 | 60.99 | 70.20 | 108 | 101 | 86.87 | 45.63 |
| Revenue growth | +32.6% | -13.1% | -35.1% | +6.8% | +16.6% | +90.4% | - |
| Other income | 9.67 | 5.37 | 2.40 | 6.60 | 2.75 | 1.81 | 0.59 |
| Total expenses | 80.09 | 58.38 | 64.85 | 91.27 | 83.99 | 67.85 | 36.98 |
| Employee cost | 0.00 | 4.87 | 5.04 | 4.04 | 2.90 | 1.95 | 1.75 |
| EBITDA | 0.76 | 2.61 | 5.35 | 16.87 | 17.30 | 19.02 | 8.65 |
| EBITDA margin | +0.9% | +4.3% | +7.6% | +15.6% | +17.1% | +21.9% | +19.0% |
| Depreciation | 0.70 | 0.46 | 0.51 | 0.52 | 0.25 | 0.09 | 0.01 |
| Interest | 2.70 | 2.24 | 1.66 | 0.51 | 0.10 | 0.15 | 0.05 |
| Profit before tax | 7.03 | 5.28 | 5.58 | 22.44 | 19.70 | 20.59 | 9.18 |
| Tax | 1.88 | 1.68 | 1.93 | 6.23 | 5.03 | 5.46 | 2.69 |
| Net profit | 5.15 | 3.60 | 3.69 | 16.21 | 14.67 | 15.13 | 6.49 |
| Net profit margin | +6.4% | +5.9% | +5.3% | +15.0% | +14.5% | +17.4% | +14.2% |
| EPS (₹) | 0.93 | 0.65 | 0.67 | 15.93 | 14.67 | 15.13 | 6.50 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 11.04 | 11.04 | 10.90 | 10.18 | 10.00 | 10.00 | 10.00 |
| Reserves & surplus | 122 | 117 | 107 | 71.63 | 47.91 | 33.25 | 18.11 |
| Shareholders' funds (net worth) | 133 | 128 | 122 | 92.11 | 57.91 | 43.25 | 28.11 |
| Secured loans | 1.30 | 0.00 | 0.15 | 0.49 | 0.93 | 0.00 | 0.00 |
| Unsecured loans | 33.99 | 32.18 | 15.55 | 11.95 | 1.00 | 3.51 | 0.00 |
| Total debt | 35.29 | 32.18 | 15.70 | 12.44 | 1.93 | 3.51 | 0.00 |
| Total liabilities | 169 | 160 | 137 | 105 | 59.84 | 46.75 | 28.11 |
| Assets | |||||||
| Gross block | 42.07 | 7.13 | 7.61 | 8.41 | 2.45 | 0.78 | 0.19 |
| Net block | 41.37 | 6.67 | 7.10 | 7.89 | 2.20 | 0.69 | 0.19 |
| Capital work in progress | 0.00 | 22.07 | 2.31 | 2.83 | 0.57 | 0.00 | 0.00 |
| Investments | 79.51 | 25.07 | 19.88 | 19.54 | 19.61 | 19.54 | 0.10 |
| Inventories | 0.00 | 0.00 | 0.84 | 1.49 | 0.00 | 0.02 | 0.83 |
| Sundry debtors | 64.20 | 89.92 | 76.76 | 78.29 | 52.11 | 48.13 | 31.22 |
| Cash & bank balances | 5.33 | 28.69 | 44.06 | 17.88 | 0.84 | 0.48 | 3.57 |
| Loans & advances | 1.07 | 0.99 | 1.24 | 1.36 | 1.12 | 0.05 | 1.08 |
| Total current assets | 70.60 | 120 | 123 | 99.02 | 54.07 | 48.68 | 36.70 |
| Total current liabilities | 22.29 | 13.38 | 16.08 | 24.08 | 22.03 | 22.16 | 9.79 |
| Net working capital | 48.31 | 106 | 107 | 74.94 | 32.04 | 26.52 | 26.91 |
| Total assets | 169 | 160 | 137 | 105 | 59.84 | 46.75 | 28.11 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 28.68 | 44.06 | 17.87 | 0.84 | 0.47 | 3.55 | 0.10 |
| Net cash from operating activities | 43.87 | (7.60) | (1.83) | (7.07) | 8.89 | 13.46 | (14.37) |
| Net cash from investing activities | (67.77) | (24.98) | 0.46 | (2.29) | (6.87) | (20.03) | (0.28) |
| Net cash from financing activities | 0.54 | 17.21 | 27.55 | 26.39 | (1.64) | 3.49 | 18.10 |
| Net change in cash | (23.35) | (15.37) | 26.19 | 17.04 | 0.38 | (3.08) | 3.44 |
| Closing cash | 5.33 | 28.69 | 44.06 | 17.88 | 0.84 | 0.48 | 3.57 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +32.6% | -13.1% | -35.1% | +6.8% | +16.6% | +90.4% | - |
| EBITDA growth | -70.9% | -51.2% | -68.3% | -2.5% | -9.0% | +119.9% | - |
| PBT growth | +33.1% | -5.4% | -75.1% | +13.9% | -4.3% | +124.3% | +274.7% |
| Net income growth | +43.1% | -2.4% | -77.2% | +10.5% | -3.0% | +133.1% | - |
| Revenue CAGR (3Y) | -9.2% | -15.6% | -6.9% | +33.3% | +95.3% | - | - |
| EBITDA CAGR (3Y) | -61.1% | -46.8% | -34.5% | +24.9% | +123.0% | - | - |
| Profitability & leverage | |||||||
| Net income margin | +6.4% | +5.9% | +5.2% | +15.0% | +14.5% | +17.4% | +14.2% |
| Return on capital employed | +6.1% | +5.1% | +6.0% | +27.9% | +37.2% | +55.4% | +58.4% |
| Return on net worth | +4.0% | +2.9% | +3.4% | +21.6% | +29.0% | +42.4% | +41.1% |
| Debt / equity | 0.26 | 0.19 | 0.13 | 0.10 | 0.05 | 0.05 | 0.00 |
| Long-term debt / equity | 0.01 | 0.01 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 |
| Interest cover | 1,010.34 | 104.19 | 34.30 | 3.12 | 0.59 | 0.79 | 0.58 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 3.29 | 8.28 | 8.76 | 19.92 | 62.72 | 179.11 | 456.30 |
| Inventory turnover | 0.00 | 145.21 | 60.26 | 145.15 | 10,129.00 | 204.40 | 109.95 |
| Debtors turnover | 1.05 | 0.73 | 0.91 | 1.66 | 2.02 | 2.19 | 2.49 |
| EPS (₹) | 0.93 | 0.65 | 0.67 | 15.93 | 14.67 | 15.13 | 6.50 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.50 | 0.00 | 0.00 |
| Book value per share (₹) | 24.09 | 23.16 | 21.61 | 80.35 | 57.91 | 43.25 | 28.11 |
To see the full year-wise statements and ratios of Balaxi Pharmaceuticals Limited, buy the company report.
Board of directors of Balaxi Pharmaceuticals Limited
Balaxi Pharmaceuticals has 6 current directors and 20 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ashish Maheshwari Also directs: Balaxi Holdings LLP, Balaxi Overseas Private Limited, Balaxi Capital Holdings Private Limited and 1 more | Managing Director | 04 May 2017 | 9 Years 6 Months | Current |
| Mangina Srinivas Rao Also directs: Droneacharya Aerial Innovations Limited, TCC Concept Limited, Isera Lifesciences Limited and 5 more | Director | 15 Sep 2020 | 6 Years 2 Months | Current |
| Minoshi Maheshwari | Director | 04 May 2017 | 9 Years 6 Months | Current |
| Kunal Mahendra Bhakta | Director | 04 May 2017 | 9 Years 6 Months | Current |
| Gandhi Gamji Also directs: Green Chemical Technologies (India) Private Limited | Director | 04 May 2017 | 9 Years 6 Months | Current |
| Akshita Surana | Director | 05 Sep 2024 | 2 Years 2 Months | Current |
Auditor
Balaxi Pharmaceuticals Limited is audited by P. Murali & Co. for the financial year 2025.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| P. Murali & Co. | FY 2025 | 007257S |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 66.00%, foreign institutional investors hold 0.00%, domestic institutional investors hold 2.60% and retail and other public shareholders hold 31.40%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 66.00% | 66.00% | 66.00% | 66.00% |
| Public | 34.00% | 34.00% | 34.00% | 34.00% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 20 Nov 2025 | 101193014 | Axis Bank Limited | ₹1.44 Cr | Open | |
| 16 Sep 2024 | 100983181 | Yes Bank Limited | ₹35 Cr | Open | |
| 26 Jul 2022 | 100634052 | Others | ₹31 Cr | Satisfied | |
| 29 Jun 2021 | 100459808 | Yes Bank Limited | ₹1 Cr | Satisfied | |
| 23 Jun 2020 | 100349613 | Others | ₹21 Lakh | Satisfied |
To see the full charge records of Balaxi Pharmaceuticals Limited, buy the company report.
Total charge records: 10 View all charges
Deals & funding
Balaxi Pharmaceuticals Limited has 13 deals on record (12 market trades, 1 funding round), with disclosed funding of ₹49.61 Cr; the latest was in March 2026.
Deals on record (5 of 13)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Dec 2025 | Market trade | ₹1.41 Cr | Buyer: Dulcet Advisory Private Limited Seller: Dulcet Advisory Private Limited |
| Jul 2025 | Market trade | ₹1.46 Cr | Buyer: Dulcet Advisory Private Limited Seller: Dulcet Advisory Private Limited |
| Jul 2025 | Market trade | ₹1.6 Cr | Buyer: Dulcet Advisory Private Limited |
| Apr 2025 | Market trade | ₹28.77 Cr | Buyer: Nexpact Limited, Multitude Growth Funds Limited, Padmavati Holdings Pvt Ltd Seller: Unico Global Opportunities Fund Limited, Padmavati Holdings Pvt Ltd |
| Apr 2025 | Market trade | ₹3.03 Cr | Buyer: Shristi Investments Pvt Ltd Seller: Unico Global Opportunities Fund Limited |
To see the full deal history of Balaxi Pharmaceuticals Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Balaxi Pharmaceuticals Limited has 1 court case on record: 1 filed by Balaxi Pharmaceuticals. All case is pending.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| Supreme Court | 1 | 0 | 1 |
Cases on record (1 of 1)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Supreme Court | Court case | Filed by the company against an individual | Pending |
To see the full case history of Balaxi Pharmaceuticals Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Balaxi Pharmaceuticals Limited has 5 MSME Form 1 returns on record between 2023 and 2024, listing 368 overdue payments to 13 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 13)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| M M Print & Pack | |||
| Lucent Biotech Limited | |||
| Glumex Pharmaceuticals Manufacturing Pvt Ltd. | |||
| Ion Healthcare Private Limited | |||
| National Laboratories Unit-Ii |
To see the full MSME payment records of Balaxi Pharmaceuticals Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Balaxi Pharmaceuticals Limited has a workforce of 80 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 80 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 | |
| FY 2018-19 |
To see the full employee and EPFO history of Balaxi Pharmaceuticals Limited, buy the company report.
GST
Balaxi Pharmaceuticals has 2 GST registrations: 2 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AABCA8305N1ZJ | Telangana | Active | 09 Jan 2018 |
| 36AABCA8305N2ZI | Telangana | Active | 20 Apr 2022 |
To see the full GST registrations and return filing status of Balaxi Pharmaceuticals Limited, buy the company report.
Recent activity
Balaxi Pharmaceuticals Limited has 38 board changes on record since 1959: 22 appointments and 16 cessations. The latest: Akshita Surana was appointed as Director on 05 Sep 2024.
48 earlier events are in the company report.
News
Frequently asked questions
Balaxi Pharmaceuticals is an active public limited company based in Hyderabad, Telangana, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 28 September 1942 (84+ years old) and is registered under CIN L25191TG1942PLC121598. Listed on NSE: BALAXI.
Balaxi Pharmaceuticals reported revenue of ₹270.17 Cr for FY 2025-26 (down 7.7% YoY) based on consolidated financials.
Balaxi Pharmaceuticals has 6 current directors:
- Ashish Maheshwari - Managing Director
- Mangina Srinivas Rao - Director
- Minoshi Maheshwari - Director
- Kunal Mahendra Bhakta - Director
- Gandhi Gamji - Director
- Akshita Surana - Director
The latest financial statements of Balaxi Pharmaceuticals on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 25 August 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Balaxi Pharmaceuticals is 36AABCA8305N1ZJ, registered in Telangana. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 36AABCA8305N2ZI (Telangana).
The CIN (Corporate Identification Number) of Balaxi Pharmaceuticals is L25191TG1942PLC121598. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Balaxi Pharmaceuticals is a listed company as per MCA records. Its shares are listed on NSE (symbol: BALAXI).
Balaxi Pharmaceuticals has 1 court case on record: 1 filed by the company. 1 is pending.
Balaxi Pharmaceuticals was incorporated on 28 September 1942, making it 84+ years old. It is registered with the Registrar of Companies, Hyderabad.
Balaxi Pharmaceuticals has 13 deals on record (12 market trades, 1 funding round), with disclosed funding of ₹49.61 Cr; the latest was in March 2026.
Akshita Surana was appointed as Director on 05 Sep 2024. Purnima Singh Singh Kamble ceased to be Director on 08 May 2024. Purnima Singh Singh Kamble was appointed as Director on 26 Mar 2021. Balaxi Pharmaceuticals has 38 board changes on record in total.

